Ironwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Ironwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

February 13, 2019 7:00 AM EST

Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million

Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected first half 2019

Advanced two GI programs into Phase III development and continued to advance three ongoing sGC Phase II programs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

... More